5th Wet AMD and Diabetic Eye Disease Drug Summit

Memo

Global biopharmaceutical leaders continue to make significant strides in retinal disease treatments; as Bayer and Regeneron make headway with its high-dose version of Eylea (Eylea HD), Roche's Vabysmo is providing strong competition and has rapidly increased its market share across wet AMD and DME. Additionally, biotechs are pioneering new breakthroughs such as Outlook Therapeutics developing bevacizumab for FDA approval in ophthalmic indications, while Ocular Therapeutix progresses innovative sustained-release drug delivery systems to extend treatment intervals and enhance patient outcomes. The 2025 Wet AMD and Diabetic Eye Disease Drug Summit is the only industry-led event dedicated to exploring the latest advancements, strategic collaborations, and cutting-edge research driving the field of retinal disease treatment forward. Join a dynamic community of 70+ global leaders, including translational, clinical, and commercial experts as they gather at this premier summit. Attendees will gain unparalleled insights into emerging therapies, adaptive trial designs, and the latest clinical studies aimed at improving treatment efficacy and patient care. URLs:Tickets: https://go.evvnt.com/2783693-2?pid=5569Brochure: https://go.evvnt.com/2783693-3?pid=5569 Date and Time: Tuesday, 18 March 2025 at 08:00 to Thursday, 20 March 2025 at 16:20 Venue details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development Prices:Drug Developer - Conference + Workshop Day: USD 4197.00,Drug Developer - Conference Only: USD 2999.00,Academic and Non-Profit - Conference + Workshop Day: USD 3597.00,Academic and Non-Profit - Conference Only: USD 2599.00,Solution Provider - Conference + Workshop Day: USD 5197.00,Solution Provider - Conference Only: USD 3799.00 Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Anton Lennikov, Faculty Instructor, Schepens Eye Research Institute, Arun Upadhyay, Chief Scientific Officer, Ocugen, Ash Jayagopal, Chief Scientific and Development Officer, Opus Genetics, Brian Levy, Chief Executive Officer, InflammX Therapeutics, Daniil Gataulin, Senior Analyst, Biotech Equity Research, Chardan Capital Markets, Fabio Baschiera, Global Clinical Leader, Ophthalmology, Bayer, Haiming Wu, Medical Device Product Development and Technology Exploration, Sanofi, Irach Taraporewala, Chief Executive Officer, EOM Pharmaceuticals, Jeffrey Heier, Chief Scientific Officer, Ocular Therapeutix, Lokendra Bengani, Senior Scientist, EyePoint Pharmaceuticals, Michael lp, Medical Director, Doheny Image Reading Center, Michael Tolentino, Co-Founder and Chief Innovation Officer, Aviceda Therapeutics, Nadia K. Waheed, Chief Medical Officer, Ocular Therapeutix, Ramanath Bhandari, Chief Executive Officer, RevOpsis, Surendra Sharma, Senior Vice President, Medical Affairs, Outlook Therapeutics, TJ Cradick Chief Technology Officer HuidaGene Therapeutics, Victor Chong, Chief Medical Officer and Executive Vice President, Clearside Biomedical